Researchers have announced a new investigational therapy called Haduvio™, which aims to help people suffering from chronic cough linked to conditions like idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). This oral medication, developed by Trevi Therapeutics, has shown promise in clinical trials by significantly reducing cough frequency in patients with these chronic conditions. For individuals who experience debilitating coughs that disrupt their daily lives, this could represent a new avenue for relief.

Chronic cough is a common and distressing issue, particularly for the estimated 140,000 people in the U.S. with IPF and the 2-3 million with RCC. Many of these individuals cough excessively—up to 1,500 times a day—which can lead to serious health complications, including increased hospital visits and a decline in overall quality of life. Haduvio works by targeting specific opioid receptors involved in the cough reflex, potentially offering a new treatment option where none currently exist.

While the results from Trevi Therapeutics are encouraging, it’s important to note that Haduvio is still in the early stages of development. Its safety and effectiveness have not yet been evaluated by regulatory authorities, meaning it is not yet available for public use. As research continues, there is hope that this therapy could eventually provide much-needed relief for those suffering from chronic cough.

Source: globenewswire.com